Mallinckrodt issued a press release on February 25 regarding the companies future, current settlement, and continuation of developing novel therapies and improving the lives of patients.
For additional information and a link to the official press release, please visit www.advancingmnk.com
Highlights (modified from a document provided by Mallinckrodt)
Mallinckrodt reached agreement in principle on terms of global settlement that would resolve all opioid-related claims against Mallinckrodt, Specialty Generics, and the Company’s other subsidiaries.
This removes significant uncertainty and enables Mallinckrodt to move ahead with strategic plans.
Specialty Generics expected to file Chapter 11 in the coming months; provides fair, orderly, efficient and legally binding resolution; Specialty Brands is not included in this process.
What This Means for You
Mallinckrodt is operating as normal – no change to how they work together.
Continuing to support customers, meet financial commitments and execute on strategic priorities.
Remain committed to improving lives of patients with innovative therapies.